Batten Disease Therapeutic Pipeline H1 2015 Market Review Research Report adds “Batten Disease – Pipeline Review, H1 2015” to its store.

The report ‘Batten Disease – Pipeline Review, H1 2015′, provides an overview of the Batten Disease’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Batten Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Batten Disease and special features on late-stage and discontinued projects. Complete report is available at .

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Order a copy of this report at (Prices start at US $ 2000 for a single user PDF) .

Companies discussed in this report include:

·         BioMarin Pharmaceutical Inc.

·         ReGenX Biosciences, LLC

Drugs profiled discussed in this report include cerliponase alfa, Gene Therapy + Bone Marrow Transplantation, Gene Therapy to Activate Tripeptidyl Peptidase 1 for Batten Disease, Small Molecules for Batten Disease, Small Molecules to Inhibit CDC42 for Juvenile Neuronal Ceroid Lipofuscinosis, XN-001.

Featured News & Press Releases:

·         Jan 12, 2015: BioMarin Provides Preliminary Data From Ongoing Phase 1/2 Pivotal Study of BMN 190 for Treatment of CLN2 Disorder, a Form of Batten Disease

·         Sep 23, 2013: BioMarin Doses First Patient in Phase 1/2 Trial With BMN 190 for the Treatment of Neuronal Ceroid Lipofuscinosis Type 2, a Form of Batten Disease

·         Apr 01, 2013: BioMarin Pharma Submits CTA For BMN-190 For Batten Disease

·         Mar 15, 2012: Combination treatment in mice shows promise for fatal neurological disorder in kids

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Batten Disease
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Batten Disease pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Explore more reports on all Therapeutics at .